Space is filling fast!Read More
The only change will be that a pre mix will be in the box. All vials of Amio that were always there will still be there. This change will occur over time. So, for a while you may see no changes.
There are occasions where non-transport of a patient after ALS treatment has begun occurs. This document serves as a best practice advisory. It does not, nor is it intended as medical direction, or to replace the authority of any medical director to create guidelines for clinical practice within his/her agency. It is strongly encouraged that each agency and its respective medical director should create a specific directive with respect to how these situations are to be handled.
It is considered that situations that result in non-transport pose a higher medical and legal risk to both the provider and patient. However, patients with capacity have the right to determine their medical treatment. This includes procedures, medication administration, and transport. The patient may choose to consent to all, some, or none of these options.
Should a situation arise where non-transport after beginning ALS treatment arises, it is recommended that online medical control be contacted as part of the decision process. Providers should refer to the specific expectations laid out by their respective medical directors.
There is currently a shortage of D50 in our region, so both UVA and SMJH will be stocking ONE D50 in their drug boxes until line of supply improves. Boxes affected will be labeled on top (like the Atropine, Epi and Dopamine changes before). Please be aware of these changes as they are going into effect immediately.
If there are questions, please contact TJEMS at 434-295-6146.
The Virginia Office of Emergency Medical Services (OEMS) is announcing a NO COST grant opportunity to licensed EMS agencies fornasal naloxone to be administered by EMS personnel. The EMS agency applying for this grant opportunity must either have a controlled substance registration (CSR) OR the operational medical director (OMD) must provide authorization for shipment of naloxone, their drug enforcement agency (DEA) number and an address for the medication to be shipped to on behalf of the awarded agency.
• Applications for funding are available through the EMS-Grant Information Funding Tool (E-GIFT), along with the NNEA User Guide available on the OEMS website at https://www.vdh.virginia.gov/oems/Agency/Grants/index.htm
• Applications must be received through E-GIFT with all appropriate e-signatures by the application deadline, September 29, 2017.
FOR MORE INFORMATION, please check our website: http://www.vdh.virginia.gov/oems/Agency/Grants/index.htm OR contact Amanda Davis, grants manager, Amanda.Davis@vdh.virginia.gov or 804-888-9106.
The Virginia Office of EMS (OEMS) recently updated its policy regarding Patient Care Reports (PCR) and data submission requirements. The revised agency policy regarding the completion of a PCR for Virginia EMS agencies is effective July 1, 2017, and remains in effect until acted on by the OEMS. This policy applies to all categories of Virginia EMS agencies (911, non-emergency, ground, air, etc.)
Please review this updated policy at: Patient Care Report Documentation and Data Submission.
For more information or questions about this revised policy, please contact Regulation and Compliance Manager Michael Berg at Michael.Berg@vdh.virginia.gov or 804-888-9131.